Dengue Vaccines 2023

Authored by
Last reviewed
June 2, 2023
Content Overview
Dengue vaccines approved in June 2023 include Dengvaxia and Qdenga

Dengue Vaccines June 2023

The World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), Pan American Health Organization (PAHO), and the European Medicine Agency (EMA) recommend dengue vaccines should be given to persons living or visiting dengue-risk areas. Since October 30, 2022, two dengue vaccines have been authorized in various countries.

Dengue Vaccines 2023

Dengvaxia® is a live attenuated tetravalent chimeric vaccine approved by the U.S. FDA and various countries.

QDENGA® is a dengue vaccine approved or authorized in Argentina, BrazilIndonesiaEurope, the U.K., and the USA.

The DV1-DV4 vaccine candidate is transitioning into a human clinical study. This new vaccine construct, which comprises Nature's gene-chip peptides bound to a quantum cluster gold nanoparticle delivery system, was shown to have an excellent safety profile in a repeat dose Good Laboratory Practice grade toxicology study using a standard industry model.

TetraVax-DV-TV003 (V180) is a live attenuated recombinant tetravalent investigational dengue vaccine conducting a phase 3 clinical trial in Brazil. Dr. Stephen Whitehead's laboratory developed the vaccine at NIH's National Institute of Allergy and Infectious Diseases.

Àvida Biotech's novel oral vaccine candidate for dengue does not require cold transport or storage and has completed proof of concept in a mouse model. In addition, the University of Buffalo's Center for Integrated Global Biomedical Sciences will provide preclinical drug development expertise.

K.M. Biologics KD-382 vaccine is a live attenuated tetravalent dengue vaccine candidate in phase 1 clinical trial that is expected to be effective against all four serotypes with a single dose. In addition, this live attenuated virus vaccine is expected to induce neutralizing antibodies and cellular immunity, similar to natural infection.

Emergex PepGNP-Dengue vaccine candidate uses 100% synthetic vaccines to 'prime' naive CD8+ T-Cells to generate virus-specific CTL (CD8+ Cytotoxic T Lymphocyte cells) to kill infected cells before productive viral infection, thus preventing viral replication and disease in the vaccinated person. The Last Visit per clinical trial protocol was performed in March 2022. Phase I/II and II/III Clinical trials for vaccine candidates are planned.

CodaVax-DENV is a next-generation tetravalent dengue vaccine candidate under development by Codagenix Inc., whose vaccine design platform has enabled precise and rational attenuation of contemporary serotypes of all four strains of dengue virus through selective codon deoptimization. With this approach, Codagenix can rationally balance all four virus serotypes to produce a safe and highly immunogenic vaccine.

Developed by Panacea Biotech in collaboration with the Indian Council of Medical Research, the Tetravalent Panacea dengue vaccine has launched phase l/ll trials in India. PTI reported a phase lll trial is likely to begin in mid-2023.

Dengue Vaccine U.S. CDC

On February 23, 2022, Wilbur Chen, MD, MSc, led the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) Dengue Vaccine Workgroup presentations: Takeda dengue vaccine (TAK-003) safety and efficacy, Workgroup considerations. Previously, Laura Adams, DVM, MPH, and Liliana Sánchez-González, MD, MPH, presented 'Clinician Outreach and Communication Activity Call on September 29, 2022. On June 24, 2021, the ACIP presented updated dengue vaccine considerations.

Dengue Vaccine Price

Pricing for Dengvaxia® is about $99 in the USA. In addition, the CDC's Vaccine for Children fund supports eligible people. And UNICEF offers various support programs worldwide. Additional vaccine price information is posted at InstantRx™.

Dengue Antivirals March 2023

A study published by the journal Nature on March 15, 2023, shows that a first-in-class antiviral candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The new data indicates JNJ-1802 is effective against all four dengue serotypes in mouse models and offers strong protection against two tested serotypes (DENV-1 and -2) in non-human primates. These findings build on Janssen Research & Development, LLC research published in Nature in 2021. JNJ-1802 is now progressing into Phase 2 clinical studies to prevent and treat dengue.

Dengue Outbreaks 2023

For the latest travel alerts regarding dengue outbreaks in 2023, visit

Dengue Vaccine News 2023

March 13, 2023 - Brazil authorized the Qdenga vaccine.

February 6, 2023 - The U.K.'s MHRA granted marketing authorization for Takeda's vaccine candidate Qdenga®.

January 28, 2023 - Costa Rica local media confirmed the Dengvaxia vaccine was commercially available at pharmacies.

December 16, 2022 - The dengue vaccine (V180) developed by the Butantan Institute (Butantan-DV) was found to be 79.6% effective in preventing the disease in Brazil, according to a phase 3 clinical study. 

October 14, 2022 - Europe's human medicines committee recommended granting marketing authorization for the QDENGA Dengue Tetravalent Vaccine (Live, for the prevention of dengue virus, serotypes 1, 2, 3, and 4 in people from four years of age. 

August 22, 2022 - The Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan, approved the QDENGA® dengue vaccine.

August 17, 2022 - Codagenix Inc. announced the U.S. DoD granted the Company a $4.4 million award to progress the development of CodaVax-DENV, its tetravalent dengue vaccine candidate.

July 1, 2022 - Emergex Vaccines Holding Limited announced that it had signed heads of terms for a collaboration with the Molecular Biology Institute of Paraná, focusing on dengue vaccinations.

      June 9, 2022 - Takeda's TAK-003 is Undergoing Regulatory Review for Potential Licensure in the European Union and Select Dengue-Endemic Countries.

      April 18, 2022 - Emergex Vaccines Holding Limited updated its first-in-human clinical trials of its Dengue and Coronavirus T cell Adaptive Vaccine candidates. In addition, the Company completed the Phase I clinical trial for its novel CD8+ T cell Dengue vaccine candidate. 

      October 4, 2021 - Clinical Infectious Diseases published: Three years efficacy and safety of Takeda's dengue vaccine candidate (TAK-003), which concluded by stating 'TAK-003 was efficacious against symptomatic dengue over three years. Efficacy declined over time but remained robust against hospitalized dengue.'

      August 23, 2019 - Study: Pre-vaccination screening strategies for using the CYD-TDV dengue vaccine: A meeting report. The meeting discussions highlighted many challenges in introducing Dengvaxia, screening test characteristics, costs of such tests combined with a 3-dose schedule, logistics, high coverage rates, vaccine confidence, and communication; more challenges than any other vaccine introduction program.

      November 14, 2018 - Preliminary data regarding a live-attenuated tetravalent dengue vaccine candidate developed by Takeda show that the vaccine may protect against all four serotypes of the infection, according to research presented at the annual meeting of the American Society of Tropical Medicine and Hygiene.

      Note: The content on this webpage is aggregated from the WHO, the U.S. CDC, research studies, and various media sources. Healthcare providers like Dr. Bob Carlso review this content for efficacy.